600195.SH
中牧股份
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 6.73
+0.30%Year over year
Reported trailing growth
- Revenue
- +4.9%
- EBITDA
- —
- EBIT
- +172.9%
- EPS
- +125.2%
- Free cash flow
- +1111.2%
- Operating cash flow
- +174.5%
Forward estimates
Based on analyst estimates
- Revenue
- -3.9%
- EBITDA
- +81.1%
- EPS
- +358.7%
Three-year CAGR
- Revenue
- +1.7%
- EBITDA
- -11.9%
- EBIT
- -25.1%
- Net income
- -32.2%
- EPS
- -32.3%
- Free cash flow
- +2435.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026